AROAF
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more
AROAF (AROAF) - Total Assets
Latest total assets as of March 2025: $98.94 Million USD
Based on the latest financial reports, AROAF (AROAF) holds total assets worth $98.94 Million USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AROAF - Total Assets Trend (2021–2025)
This chart illustrates how AROAF’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AROAF - Asset Composition Analysis
Current Asset Composition (March 2025)
AROAF's total assets of $98.94 Million consist of 62.6% current assets and 37.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.3% |
| Accounts Receivable | $13.82 Million | 14.0% |
| Inventory | $7.52 Million | 7.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.33 Million | 12.5% |
| Goodwill | $5.03 Million | 5.1% |
Asset Composition Trend (2021–2025)
This chart illustrates how AROAF's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AROAF's current assets represent 62.6% of total assets in 2025, an increase from 61.2% in 2021.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 44.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, a decrease from 21.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 14.0% of total assets.
AROAF Competitors by Total Assets
Key competitors of AROAF based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
AROAF - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - AROAF generates 0.78x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AROAF is currently not profitable relative to its asset base.
AROAF - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.62 | 7.26 | - |
| Quick Ratio | 5.81 | 6.40 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $52.59 Million | $ 54.60 Million | - |
AROAF - Advanced Valuation Insights
This section examines the relationship between AROAF's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.16 |
| Latest Market Cap to Assets Ratio | 1.04 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | $98.94 Million |
| Market Capitalization | $103.30 Million USD |
Valuation Analysis
Above Book Valuation: The market values AROAF's assets above their book value (1.04 x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: AROAF's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for AROAF (2021–2025)
The table below shows the annual total assets of AROAF from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $98.94 Million | -2.89% |
| 2024-03-31 | $101.88 Million | -6.60% |
| 2023-03-31 | $109.07 Million | +4.17% |
| 2022-03-31 | $104.71 Million | +43.19% |
| 2021-03-31 | $73.12 Million | -- |